Quality of life of testicular cancer survivors and the relationship with sociodemographics, cancer-related variables, and life events

Fleer, Joke; Hoekstra, Harald J.; Sleijfer, Dirk; Tuinman, Marrit A.; Klip, Ed C.; Hoekstra-Weebers, Josette E. H. M.

doi:10.1007/s00520-005-0879-3

Cited by 55 publications

(39 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…49 Dahl et al 14 reported that neurotoxic adverse effects, anxiety/depression, and musculoskeletal issues were associated with poor quality of life. Fleer et al 50 found that chronic disease was also a quality-of-life correlate, although an association with number of conditions was not evaluated.…”

Section: Ahos and Self-reported Healthmentioning

confidence: 99%

Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy

Fung

Sesso

Williams

et al. 2017

JCO

108

View full text Add to dashboard Cite

To provide new information on adverse health outcomes (AHOs) in testicular cancer survivors (TCSs) after four cycles of etoposide and cisplatin (EPX4) or three or four cycles of bleomycin, etoposide, cisplatin (BEPX3/BEPX4). MethodsNine hundred fifty-two TCSs . 1 year postchemotherapy underwent physical examination and completed a questionnaire. Multinomial logistic regression estimated AHOs odds ratios (ORs) in relation to age, cumulative cisplatin and/or bleomycin dose, time since chemotherapy, sociodemographic factors, and health behaviors. ResultsMedian age at evaluation was 37 years; median time since chemotherapy was 4.3 years. Chemotherapy consisted largely of BEPX3 (38.2%), EPX4 (30.9%), and BEPX4 (17.9%). None, one to two, three to four, or five or more AHOs were reported by 20.4%, 42.0%, 25.1%, and 12.5% of TCSs, respectively. Median number after EPX4 or BEPX3 was two (range, zero to nine and zero to 11, respectively; P . .05) and two (range, zero to 10) after BEPX4. When comparing individual AHOs for EPX4 versus BEPX3, Raynaud phenomenon (11.6% v 21.4%; P , .01), peripheral neuropathy (29.2% v 21.4%; P = .02), and obesity (25.5% v 33.0%; P = .04) differed. Larger cumulative bleomycin doses (OR, 1.44 per 90,000 IU) were significantly associated with five or more AHOs. Increasing age was a significant risk factor for one to two, three to four, or five or more AHOs versus zero AHOs (OR, 1.22, 1.50, and 1.87 per 5 years, respectively; P , .01); vigorous physical activity was protective (OR, 0.62, 0.51, and 0.41, respectively; P , .05). Significant risk factors for three to four and five or more AHOs included current (OR, 3.05 and 3.73) or former (OR, 1.61 and 1.76) smoking (P , .05). Self-reported health was excellent/very good in 59.9% of TCSs but decreased as AHOs increased (P , .001). ConclusionNumbers of AHOs after EPX4 or BEPX3 appear similar, with median follow-up of 4.3 years. A healthy lifestyle was associated with reduced number of AHOs.

show abstract

Section: Ahos and Self-reported Healthmentioning

confidence: 99%

Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy

Fung

Sesso

Williams

et al. 2017

JCO

108

View full text Add to dashboard Cite

show abstract

“…Most studies indicate that overall health-related quality of life (QOL) is similar among testis cancer survivors and the general population [1][2][3][4][5][6][7][8][9]. Although QOL clearly deteriorates at the time of diagnosis and during treatment, it subsequently returns to normal levels, as defined by matched controls or the general age-matched population.…”

mentioning

confidence: 96%

Quality of life among testis cancer survivors

Gilligan

2015

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

“…Limited evidence suggests that although treatment is associated with a significantly increased risk of certain treatment-related side-effects (eg, fertility, neurotoxicity, and Raynaud's phenomena), 10,12 post-treatment overall quality of life may not be adversely affected by treatment approach. [13][14][15][16][17] In addition, the few prospective studies that have been published suggest that although quality of life is adversely affected during adjuvant chemotherapy and radiation therapy, levels tend to return to baseline after the completion of treatment. 16,18,19 However, several reports suggest that survivors are more likely to experience some adverse outcomes, such as anxiety, 20 chronic fatigue, 21 and sexual dysfunction.…”

mentioning

confidence: 99%

The Effects of Testicular Cancer Treatment on Health-related Quality of Life

Vidrine

Hoekstra-Weebers

Hoekstra

et al. 2010

Urology

View full text Add to dashboard Cite

Quality of life of testicular cancer survivors and the relationship with sociodemographics, cancer-related variables, and life events

Abstract: Quality of life of testicular cancer survivors and the relationship with sociodemographics, cancer-related variables, and life events

Cited by 55 publications

References 31 publications

Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy

Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy

Quality of life among testis cancer survivors

The Effects of Testicular Cancer Treatment on Health-related Quality of Life

Contact Info

Product

Resources

About